Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from α-synuclein in vitro

Biochemistry

Volumn 41, Issue 5, 2002, Pages 1502-1511

  Cohlberg, Jeffrey A ^a   Li, Jie ^a   Uversky, Vladimir N ^a   Fink, Anthony L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRILS;

CATALYSTS; NEUROLOGY; POLYMERS; REACTION KINETICS;

DISEASES;

ALPHA SYNUCLEIN; AMYLOID; DEXTRAN SULFATE; FLUORESCEIN; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN; POLYMER;

AMYLOIDOSIS; ARTICLE; BINDING AFFINITY; CATALYST; DEGENERATIVE DISEASE; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; DOPAMINERGIC NERVE CELL; FIBER; KINETICS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN INTERACTION; SUBSTANTIA NIGRA;

ALPHA-SYNUCLEIN; AMINO ACID SUBSTITUTION; AMYLOID; ANIMALS; CATTLE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCOSAMINOGLYCANS; HEPARIN; HUMANS; KINETICS; MICROSCOPY, ELECTRON; MUTAGENESIS, SITE-DIRECTED; NERVE TISSUE PROTEINS; PARKINSON DISEASE; POLYMERS; RECOMBINANT PROTEINS; SPECTROMETRY, FLUORESCENCE; SWINE; SYNUCLEINS;

EID: 0037022186     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi011711s     Document Type: Article

References (71)

1. Review: Amyloidogenesis-unquestioned answers and unanswered questions
2. Review: Modulating factors in amyloid-beta fibril formation
3. Induction of perlecan gene expression precedes amyloid formation during experimental murine AA amyloidogenesis
4. Experimental AA amyloidogenesis is associated with differential expression of extracellular matrix genes
5. Co-deposition of basement membrane components during the induction of murine splenic AA amyloid
6. Characterization of tissue and plasma glycosaminoglycans during experimental AA amyloidosis and acute inflammation. Qualitative and quantitative analysis
7. The sulfate moieties of glycosaminoglycans are critical for the enhancement of beta-amyloid protein fibril formation
8. Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer's disease, accelerates A beta fibril formation, and maintains A beta fibril stability
9. Agrin binds to beta-amyloid (Abeta), accelerates abeta fibril formation, and is localized to Abeta deposits in Alzheimer's disease brain
10. Interactions of Alzheimer amyloid-beta peptides with glycosaminoglycans: Effects on fibril nucleation and growth
11. pH-dependent binding of synthetic beta-amyloid peptides to glycosaminoglycans
12. Binding of vascular heparan sulfate proteoglycan to Alzheimer's amyloid precursor protein is mediated in part by the N-terminal region of A4 peptide
13. Binding of secreted human neuroblastoma proteoglycans to the Alzheimer's amyloid A4 peptide
14. Identification and regulation of the high affinity binding site of the Alzheimer's disease amyloid protein precursor (APP) to glycosaminoglycans
15. Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease
16. Proteoglycan-mediated inhibition of A beta proteolysis. A potential cause of senile plaque accumulation
17. Heparin-binding properties of the amyloidogenic peptides Abeta and amylin. Dependence on aggregation state and inhibition by Congo red
18. Structural prerequisites for serum amyloid A fibril formation
19. Circular-dichroism studies on two murine serum amyloid A proteins
20. Expression and analysis of heparin-binding regions of the amyloid precursor protein of Alzheimer's disease
21. Identification of heparin-binding domains in the amyloid precursor protein of Alzheimer's disease by deletion mutagenesis and peptide mapping
22. Effect of amino acid substitutions on Alzheimer's amyloid-beta peptide-glycosaminoglycan interactions
23. Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans
24. Filamentous nerve cell inclusions in neurodegenerative diseases: Tauopathies and alpha-synucleinopathies
25. Phosphorylation of tau protein by purified p34cdc28 and a related protein kinase from neurofilaments
26. Differential effect of phosphorylation and substrate modulation on tau's ability to promote microtubule growth and nucleation
27. Protein kinase FA/glycogen synthase kinase-3 alpha after heparin potentiation phosphorylates tau on sites abnormally phosphorylated in Alzheimer's disease brain
28. Characterization of mAb AP422, a novel phosphorylation-dependent monoclonal antibody against tau protein
29. Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases
30. Alzheimer-like changes in microtubule-associated protein Tau induced by sulfated glycosaminoglycans. Inhibition of microtubule binding, stimulation of phosphorylation, and filament assembly depend on the degree of sulfation
31. Polymerization of tau into filaments in the presence of heparin: The minimal sequence required for tau-tau interaction
32. Rapid assembly of Alzheimer-like paired helical filaments from microtubule-associated protein tau monitored by fluorescence in solution
33. Basic fibroblast growth factor binds to filamentous inclusions of neurodegenerative diseases
34. Fatal attractions: Abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia
35. Alpha-synuclein in Lewy body disease and Alzheimer's disease
36. Molecular pathogenesis of movement disorders: Are protein aggregates a common link in neuronal degeneration?
37. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded
38. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes
39. Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation
40. Alpha-synuclein membrane interactions and lipid specificity
41. Interaction of human alpha-synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis
42. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons
43. Chaperone-like activity of synucleins
44. Regulation of phospholipase D2: Selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins
45. Alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356
46. Microtubule-associated protein 1B is a component of cortical Lewy bodies and binds alphasynuclein filaments
47. Synphilin-I associates with alphasynuclein and promotes the formation of cytosolic inclusions
48. Accelerated in vitro fibril formation by a mutant alphasynuclein linked to early-onset Parkinson disease
49. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid
50. Synthetic filaments assembled from C-terminally truncated alpha-synuclein
51. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alphasynuclein protein implicated in Parkinson's disease
52. Human recombinant NACP/alpha-synuclein is aggregated and fibrillated in vitro: Relevance for Lewy body disease
53. Mutant and wild-type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro
54. Both familial Parkinson's disease mutations accelerate alphasynuclein aggregation
55. Fiber diffraction of synthetic alphasynuclein filaments shows amyloid-like cross-beta conformation
56. Parkinson's disease-associated alpha-synuclein is more fibrillogenic than beta- and gamma-synuclein and cannot cross-seed its homologues
57. Evidence for a partially folded intermediate in α-synuclein fibril formation
58. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy
59. Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: Detection of amyloid aggregation in solution
60. Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavin T1
61. Sequestration of RNA in Alzheimer's disease neurofibrillary tangles and senile plaques
62. RNA sequestration to pathological lesions of neurodegenerative diseases
63. Molecular modeling of protein-glycosaminoglycan interactions
64. Structural properties of the heparin-binding domains of human apolipoprotein E
65. Optical conformation of heparin and heparin complexes with cationic dyes, amines and protein models
66. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease
67. Identification of two distinct synucleins from human brain
68. Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein
69. Alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease
70. The presence of chondroitin sulfate A and C within axon terminals in the superior olivary nuclei of the adult dog
71. Effect of familial parkinson's disease point mutations A30P and A53T on the structural properties, aggregation and fibrillation of human α-synuclein